Skip to main content
logo
UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
18.87
+0.77 (4.25%)
At close: Sep 18, 2025, 4:00 PM EDT
18.40
-0.47 (-2.49%)
After-hours: Sep 18, 2025, 7:17 PM EDT

UroGen Pharma Revenue

UroGen Pharma had revenue of $24.22M in the quarter ending June 30, 2025, with 10.83% growth. This brings the company's revenue in the last twelve months to $94.24M, up 10.85% year-over-year. In the year 2024, UroGen Pharma had annual revenue of $90.40M with 9.29% growth.

Revenue (ttm)
$94.24M
Revenue Growth
+10.85%
P/S Ratio
9.47
Revenue / Employee
$401,013
Employees
235
Market Cap
873.00M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202490.40M7.69M9.29%
Dec 31, 202382.71M18.36M28.52%
Dec 31, 202264.36M16.32M33.96%
Dec 31, 202148.04M36.24M307.17%
Dec 31, 202011.80M11.78M65,450.00%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
UnitedHealth Group422.82B
Johnson & Johnson90.63B
Merck & Co.63.62B
AbbVie58.33B
AstraZeneca56.50B
Novartis AG55.19B
Eli Lilly and Company53.26B
Novo Nordisk49.11B
Revenue Rankings

URGN News

More News